Respiratory syncytial virus (RSV) is a negative-stranded, RNA-based respiratory paramyxovirus with ten genes encoding 11 proteins. Three proteins are present in the viral envelope, including the ...
(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...
RSV, or respiratory syncytial virus, is a common cause of coughs and colds which can also lead to severe lung infections like ...
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...
Most people notice this when air pressure changes rapidly, such as when a plane ascends or descends. This happens because the pressurization of the cabin isn't perfect, and the ear pressure is higher ...
Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...
The good news is that even as cases rise and will likely continue to, new as well as tried and true vaccines are available to target COVID-19, influenza and respiratory syncytial virus ...
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback